NASDAQ:HRMY Harmony Biosciences (HRMY) Stock Price, News & Analysis → How to camouflage a factory of 53,000 workers (From Stansberry Research) (Ad) Free HRMY Stock Alerts $28.38 -0.85 (-2.91%) (As of 09:52 AM ET) Add Compare Share Share Today's Range$28.25▼$28.9050-Day Range$28.85▼$35.0652-Week Range$18.61▼$39.26Volume16,780 shsAverage Volume369,957 shsMarket Capitalization$1.61 billionP/E Ratio13.39Dividend YieldN/APrice Target$40.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Harmony Biosciences alerts: Email Address Harmony Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside39.0% Upside$40.63 Price TargetShort InterestBearish20.65% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.24Based on 5 Articles This WeekInsider TradingSelling Shares$389,536 Sold Last QuarterProj. Earnings Growth31.33%From $3.00 to $3.94 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.20 out of 5 starsMedical Sector139th out of 907 stocksPharmaceutical Preparations Industry48th out of 421 stocks 3.3 Analyst's Opinion Consensus RatingHarmony Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, no hold ratings, and 2 sell ratings.Amount of Analyst CoverageHarmony Biosciences has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted20.65% of the float of Harmony Biosciences has been sold short.Short Interest Ratio / Days to CoverHarmony Biosciences has a short interest ratio ("days to cover") of 17.5, which indicates bearish sentiment.Change versus previous monthShort interest in Harmony Biosciences has recently increased by 4.27%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldHarmony Biosciences does not currently pay a dividend.Dividend GrowthHarmony Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HRMY. Previous Next 3.5 News and Social Media Coverage News SentimentHarmony Biosciences has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Harmony Biosciences this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for HRMY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harmony Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $389,536.00 in company stock.Percentage Held by Insiders30.80% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Harmony Biosciences are expected to grow by 31.33% in the coming year, from $3.00 to $3.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harmony Biosciences is 13.79, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.87.Price to Earnings Ratio vs. SectorThe P/E ratio of Harmony Biosciences is 13.79, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 177.61.Price to Earnings Growth RatioHarmony Biosciences has a PEG Ratio of 0.40. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHarmony Biosciences has a P/B Ratio of 3.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchHow to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."Get the full story here. About Harmony Biosciences Stock (NASDAQ:HRMY)Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Read More HRMY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HRMY Stock News HeadlinesApril 22, 2024 | msn.comHarmony Biosciences to Unveil Q1 2024 Financial ResultsApril 22, 2024 | americanbankingnews.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Rating of "Moderate Buy" by AnalystsApril 25, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."April 16, 2024 | finance.yahoo.comHARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024April 15, 2024 | msn.comHarmony Biosciences Secures Exclusive Rights to Promising Narcolepsy TreatmentApril 12, 2024 | investing.comHarmony Biosciences secures rights to narcolepsy treatmentApril 11, 2024 | msn.comHarmony inks licensing deal for sleep disorder therapyApril 11, 2024 | finance.yahoo.comHARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONISTApril 25, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."April 11, 2024 | prnewswire.comHARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONISTApril 8, 2024 | msn.comHarmony Biosciences Launches Phase 3 Trial for Potential Prader-Willi Syndrome TreatmentApril 3, 2024 | finance.yahoo.comHARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROMEApril 1, 2024 | msn.comHarmony Biosciences to Spotlight Innovations at Needham Virtual Healthcare ConferenceMarch 28, 2024 | markets.businessinsider.comEvaluating Harmony Biosciences: Insights From 8 Financial AnalystsMarch 26, 2024 | finance.yahoo.comHARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCEMarch 19, 2024 | benzinga.comInsider Activity Update: Jeffrey Dierks Executes Options Exercise, Resulting In $279K At Harmony BiosciencesMarch 19, 2024 | finance.yahoo.comHarmony Biosciences Holdings Inc's Chief Commercial Officer Sells Company SharesMarch 17, 2024 | finance.yahoo.comHRMY Oct 2024 35.000 putMarch 16, 2024 | finance.yahoo.comHRMY Apr 2024 30.000 putMarch 16, 2024 | finance.yahoo.comHRMY Jul 2024 30.000 putMarch 6, 2024 | morningstar.comHarmony Biosciences Holdings Inc Ordinary Shares HRMYMarch 6, 2024 | msn.comHarmony Biosciences Set to Share Insights at Upcoming Investor ConferencesFebruary 28, 2024 | prnewswire.comHARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCESFebruary 26, 2024 | msn.comHarmony Biosciences' Narcolepsy Drug for Children Gets FDA Priority ReviewFebruary 24, 2024 | msn.comHarmony Biosciences Holdings (HRMY) Price Target Increased by 6.29% to 43.10February 22, 2024 | finance.yahoo.comHarmony Biosciences Holdings Inc (HRMY) Reports Robust Revenue Growth in Q4 and Full Year 2023February 22, 2024 | finance.yahoo.comHarmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesSee More Headlines Receive HRMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/25/2024Next Earnings (Confirmed)4/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HRMY CUSIPN/A CIK1802665 Webwww.harmonybiosciences.com Phone484-539-9800FaxN/AEmployees246Year FoundedN/APrice Target and Rating Average Stock Price Target$40.63 High Stock Price Target$59.00 Low Stock Price Target$27.00 Potential Upside/Downside+39.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$2.12 Trailing P/E Ratio13.79 Forward P/E Ratio9.74 P/E Growth0.4Net Income$128.85 million Net Margins22.16% Pretax Margin29.79% Return on Equity27.49% Return on Assets16.83% Debt Debt-to-Equity Ratio0.38 Current Ratio2.75 Quick Ratio2.72 Sales & Book Value Annual Sales$582.02 million Price / Sales2.85 Cash Flow$2.64 per share Price / Cash Flow11.06 Book Value$7.97 per share Price / Book3.67Miscellaneous Outstanding Shares56,790,000Free Float39,299,000Market Cap$1.66 billion OptionableOptionable Beta0.73 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Jeffrey S. Aronin (Age 56)Founder & Non-Executive Chairman Comp: $19.6kDr. Jeffrey M. Dayno M.D. (Age 67)President, CEO & Director Comp: $762.15kMr. Jeffrey Dierks M.B.A. (Age 52)Executive VP & Chief Commercial Officer Comp: $662.1kMr. Andrew Serafin J.D. (Age 49)M.B.A., Executive VP & Chief Strategy Officer Comp: $605.42kMr. David BradshawHead of Technical OperationsLuis SanayHead of Investor RelationsMr. Christian UlrichGeneral Counsel & Corporate SecretaryMs. Tricia GloverChief Compliance OfficerMs. Audrey Murphy SPHRHead of Human ResourcesMs. Cate McCanlessHead of Corporate Affairs & Public PolicyMore ExecutivesKey CompetitorsAvadel PharmaceuticalsNASDAQ:AVDLSupernus PharmaceuticalsNASDAQ:SUPNAmneal PharmaceuticalsNASDAQ:AMRXStructure TherapeuticsNASDAQ:GPCRTaro Pharmaceutical IndustriesNYSE:TAROView All CompetitorsInsiders & InstitutionsParadiem LLCSold 13,101 shares on 4/23/2024Ownership: 0.165%Rice Hall James & Associates LLCSold 10,709 shares on 4/23/2024Ownership: 0.100%Oakworth Capital Inc.Bought 5,107 shares on 4/22/2024Ownership: 0.017%Hedeker Wealth LLCBought 78,223 shares on 4/19/2024Ownership: 0.138%Allspring Global Investments Holdings LLCBought 397 shares on 4/18/2024Ownership: 0.062%View All Insider TransactionsView All Institutional Transactions HRMY Stock Analysis - Frequently Asked Questions Should I buy or sell Harmony Biosciences stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harmony Biosciences in the last year. There are currently 2 sell ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HRMY shares. View HRMY analyst ratings or view top-rated stocks. What is Harmony Biosciences' stock price target for 2024? 8 analysts have issued twelve-month price targets for Harmony Biosciences' stock. Their HRMY share price targets range from $27.00 to $59.00. On average, they predict the company's stock price to reach $40.63 in the next twelve months. This suggests a possible upside of 39.0% from the stock's current price. View analysts price targets for HRMY or view top-rated stocks among Wall Street analysts. How have HRMY shares performed in 2024? Harmony Biosciences' stock was trading at $32.30 at the start of the year. Since then, HRMY stock has decreased by 9.5% and is now trading at $29.23. View the best growth stocks for 2024 here. When is Harmony Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024. View our HRMY earnings forecast. How can I listen to Harmony Biosciences' earnings call? Harmony Biosciences will be holding an earnings conference call on Tuesday, April 30th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Harmony Biosciences' earnings last quarter? Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) posted its earnings results on Thursday, February, 22nd. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.74 by $0.29. The firm earned $168.40 million during the quarter, compared to analysts' expectations of $168.90 million. Harmony Biosciences had a trailing twelve-month return on equity of 27.49% and a net margin of 22.16%. The company's quarterly revenue was up 31.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.01 EPS. What ETFs hold Harmony Biosciences' stock? ETFs with the largest weight of Harmony Biosciences (NASDAQ:HRMY) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Janus Henderson Small Cap Growth Alpha ETF (JSML), Invesco S&P SmallCap 600 GARP ETF (GRPZ), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco S&P SmallCap Health Care ETF (PSCH) and Pacer US Small Cap Cash Cows 100 ETF (CALF).iShares U.S. Pharmaceuticals ETF (IHE). What guidance has Harmony Biosciences issued on next quarter's earnings? Harmony Biosciences updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $700.0 million-$720.0 million, compared to the consensus revenue estimate of $712.3 million. What other stocks do shareholders of Harmony Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Harmony Biosciences investors own include Advance Auto Parts (AAP), Advanced Micro Devices (AMD), Boeing (BA), Berry Global Group (BERY), Bunge Global (BG), Carrier Global (CARR), Commercial Metals (CMC), Canadian Solar (CSIQ), Deere & Company (DE) and Eastman Chemical (EMN). When did Harmony Biosciences IPO? Harmony Biosciences (HRMY) raised $101 million in an initial public offering on Wednesday, August 19th 2020. The company issued 4,700,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler acted as the underwriters for the IPO. Who are Harmony Biosciences' major shareholders? Harmony Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Paradiem LLC (0.17%), Hedeker Wealth LLC (0.14%), Rice Hall James & Associates LLC (0.10%), Allspring Global Investments Holdings LLC (0.06%), Los Angeles Capital Management LLC (0.04%) and Hennion & Walsh Asset Management Inc. (0.03%). Insiders that own company stock include Andreas Wicki, Jack Nielsen, Jeffrey Dierks, Jeffrey M Dayno, Jeffrey M Dayno, John C Jacobs and John C Jacobs. View institutional ownership trends. How do I buy shares of Harmony Biosciences? Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HRMY) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
